REGN: Core Immunology Cash Flows Will Support Pipeline And Oncology Upside

Regeneron Pharmaceuticals' updated analyst fair value has shifted lower by about $42 to $833, as analysts factor in reduced expectations for the fianlimab program after recent Phase 3 trial disappointments, softer modeled revenue growth and margins, and a lower assumed future P/E multiple.

Analyst Commentary

Recent research on Regeneron Pharmaceuticals centers on the impact of fianlimab trial results, competitive pressures around key franchises, and how these factors feed into earnings forecasts and valuation multiples. Analysts are split between those who see the recent setbacks as a reset that leaves the core business intact and those who view them as evidence of higher execution risk and weaker pipeline visibility.

Bullish Takeaways

Bullish analysts highlight Regeneron Pharmaceuticals' core commercial assets, including Dupixent and Eylea HD, as important supports for earnings, even as expectations for the LAG-3 and fianlimab programs are reduced in their models.
Some research points to continued Dupixent growth, energized lifecycle initiatives, and an expected royalty step up from Sanofi as helping to underpin cash flow and offering support to valuation despite pipeline disappointments.
JPMorgan notes that expectations for the LAG-3 program had already reset lower in recent months, which in its view helps limit downside pressure as revenue from the trial is removed from its model.
Bullish analysts also stress Regeneron's cash position as a cushion that can support ongoing R&D and potential business development, which they see as relevant for long term growth options and downside support for the stock.

Bearish Takeaways

Bearish analysts focus on the failed Phase 3 fianlimab and LAG-3 melanoma trials as key reasons for multiple price target cuts, citing reduced revenue contribution from these programs and a hit to confidence in Regeneron's pipeline execution.
Several firms explicitly lower assumed P/E multiples, pointing to longer term earnings growth concerns, sector multiple compression, and the view that high profile clinical disappointments may justify a lower valuation framework.
Some commentary flags ongoing risk to the Eylea franchise, including potential erosion from biosimilar competition and the possibility that earnings could come in below prior expectations in 2026 to 2027, which feeds into more cautious targets.
Research also points to external pressures, such as increased competitive intensity in atopic dermatitis from potential next generation IL 13 therapies and regulatory risk tied to proposed Medicare drug price negotiation rules, as additional overhangs on Regeneron Pharmaceuticals' growth outlook and market multiple.

What’s in the News for Regeneron Pharmaceuticals

Regeneron Pharmaceuticals reported Q1 2026 revenue of US$3.61b and EPS of US$9.47, ahead of consensus estimates. Management approved a new US$3b share repurchase program and highlighted contributions from Dupixent, Libtayo, Eylea HD and collaborations. (Source: Q1 2026 earnings story)
Regeneron and Sanofi reported that profits from their collaboration, led by Dupixent, rose 42% in the most recent quarter compared with overall revenue growth. Repayment of development costs to Sanofi is expected to lift Regeneron’s share of collaboration revenue. (Source: Sanofi collaboration profit story)
The FDA and EMA accepted regulatory submissions for cemdisiran to treat generalized myasthenia gravis. The FDA granted Priority Review with a target decision date in November 2026, and a European Commission decision is expected in the second half of 2027. (Source: cemdisiran gMG submission story)
The World Health Organization prioritized Regeneron’s antibody maftivimab for clinical trials against Bundibugyo ebolavirus during an ongoing public health emergency. This underscores the company’s role in Ebola treatment alongside mixed outcomes from the fianlimab Phase 3 melanoma program. (Source: maftivimab and fianlimab story)
CytomX expanded its collaboration with Regeneron to develop conditionally activated bispecific cancer therapies. The deal’s potential value increased to about US$4b in milestones and royalties, with six additional target options added. (Source: CytomX collaboration story)

Valuation Changes for Regeneron Pharmaceuticals

Fair Value: Analyst fair value for Regeneron Pharmaceuticals has been reduced from $875.31 to $833.31, a decline of about 4.8%.
Discount Rate: The discount rate has risen slightly from 7.21% to 7.24%, reflecting a modestly higher required return in updated models.
Revenue Growth: Modeled long term revenue growth has been trimmed from 9.36% to 9.15%, indicating slightly more conservative sales assumptions.
Net Profit Margin: Forecast net profit margin has eased from 31.18% to 30.78%, pointing to marginally lower expected profitability.
Future P/E: The future P/E multiple applied in analyst models has been lowered from 17.55x to 16.52x, which brings down the implied valuation for Regeneron Pharmaceuticals.

4 views

Key Takeaways

Expanding pipeline, new indications, and emerging market access position the company for sustained revenue growth and increased long-term earnings.
Ongoing R&D investment and advanced manufacturing provide cost advantages and margin protection amid shifts toward breakthrough technologies and personalized medicine.
Heavy reliance on EYLEA amid intensifying competition, regulatory delays, and pricing pressures threatens revenue sustainability, while pipeline and market uncertainties cloud future growth prospects.

Catalysts

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.What are the underlying business or industry changes driving this perspective?

Regeneron's broad and advancing pipeline-including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity-positions the company to benefit from demographic-driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline-driven earnings upside.
Rapid growth and expansion of Dupixent (with new indications in COPD, CSU, and bullous pemphigoid) has significantly increased the addressable patient population, but only a small fraction of eligible patients are currently being treated, leaving substantial runway for volume growth, especially as global healthcare access expands-supportive of higher long-term revenues and margins.
The successful ramp of EYLEA HD, which is gaining physician adoption due to its clinical profile and durability, along with anticipated regulatory approvals for label enhancements (pending resolution of manufacturing site issues), could help offset patent/biosimilar pressures on legacy EYLEA, supporting stabilization and potential growth in core revenue and sustaining healthy margins over the next several years.
Significant reinvestment in internal R&D, advanced manufacturing, and in-house biologics and gene therapy platforms provides Regeneron with cost advantages and rapid scalability, enhancing margin protection as the industry accelerates adoption of new biotechnologies (AI, big data, CRISPR) and as regulatory pathways become more favorable for differentiated breakthrough therapies.
Expansion into high-growth indications such as obesity and cardiometabolic diseases (via GLP-1/GIP, novel antibody combinations) and strategic development for emerging market access (benefiting from increased global healthcare spending) create new multi-billion-dollar revenue streams likely underappreciated by the market, supporting higher long-term earnings and revenue diversification.

Regeneron Pharmaceuticals Earnings and Revenue Growth

Regeneron Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Regeneron Pharmaceuticals's revenue will grow by 9.2% annually over the next 3 years.
Analysts assume that profit margins will increase from 29.6% today to 30.8% in 3 years time.
Analysts expect earnings to reach $6.0 billion (and earnings per share of $57.25) by about June 2029, up from $4.4 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $7.7 billion in earnings, and the most bearish expecting $4.9 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 16.6x on those 2029 earnings, up from 14.2x today. This future PE is lower than the current PE for the US Biotechs industry at 16.8x.
Analysts expect the number of shares outstanding to decline by 1.69% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.24%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

EYLEA faces ongoing branded and biosimilar competition as well as continued unit demand declines, with management explicitly cautioning that pricing, patient affordability issues, and competitive pressures are expected to negatively impact future U.S. net product sales; this poses a risk of significant revenue and earnings erosion as EYLEA represents a large portion of current revenue.
Delays in regulatory approvals for EYLEA HD enhancements-due to FDA observations at key third-party manufacturing sites (Catalent/Novo Nordisk Indiana)-create near-term uncertainty and may postpone critical product improvements and label expansions essential to offset competitive headwinds, pressuring near
to long-term revenue and margin growth.
The company is significantly increasing internal R&D and U.S. manufacturing investments (over $7 billion), but with pipeline skepticism from analysts regarding the commercial value of late-stage assets relative to high annual R&D spend, there is risk of insufficient pipeline diversification or failure to generate new blockbusters, potentially limiting future earnings growth and compressing net margins.
External policy and pricing risks such as Medicare's MFN (Most Favored Nation) pricing, increased global pressure on drug prices, and uncertainty around reimbursement-particularly for key U.S. products like EYLEA-could compress net selling prices and reduce overall revenue and margins, especially if Regeneron cannot influence pricing in OUS (outside U.S.) markets managed by partners like Bayer.
The branded anti-VEGF market is experiencing share erosion to lower-cost alternatives (e.g., Avastin) due to patient affordability and assistance funding gaps, while ongoing and heightened biosimilar competition further threaten market share for established franchises, putting long-term revenue and operating income under sustained downward pressure.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $833.31 for Regeneron Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $1000.0, and the most bearish reporting a price target of just $641.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $19.4 billion, earnings will come to $6.0 billion, and it would be trading on a PE ratio of 16.6x, assuming you use a discount rate of 7.2%.
Given the current share price of $618.03, the analyst price target of $833.31 is 25.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Regeneron Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead